Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound

This article was originally published in PharmAsia News

Executive Summary

Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.

You may also be interested in...

Eisai Buys U.S. Biotech AkaRx With Chinese And Indian Markets In Sight

Eisai plans to acquire U.S. biotech AkaRx for $225 million in a move that will give the Japanese outfit access to AKR-501, a novel small-molecule thrombopoietin mimetic under development to treat thrombocytopenia resulting from viral hepatitis and other problems

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?

Astellas Regains Japan Losses With Xtandi Expansion

Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts